SCHEMBL14067698

SCHEMBL14067698

CN1C=C(C(N)=O)Cc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 1/20 0.42
PABPC1 P11940 1/20 0.42
BLM P54132 1/20 0.42
HSD17B3 P37058 2/20 0.37
TDP1 Q9NUW8 2/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.36
PARP1 P09874 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767870 0.85 NOTUM (0.44) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL12857207 0.83 NOTUM (0.42) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL12426331 0.77 ACHE (0.57) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL861720 0.77 ALDH1A1 (0.39) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL14067671 0.75 LMNA (0.40) NOTUMKMT2AKDM4EMAPTALDH1A1
SCHEMBL17883625 0.73 KDM4E (0.37) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL9551608 0.73 NOTUM (0.41) NOTUMMEN1KMT2AKDM4EMAPT
SCHEMBL26366444 0.72 ALDH1A1 (0.41) NOTUMMEN1KMT2AKDM4EALDH1A1
SCHEMBL17883561 0.71 NPC1 (0.41) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL24247562 0.70 KDM4E (0.47) NOTUMMEN1KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020070672-A1 HYDRIDE DONORS AS AN ADDITIVE FOR REDUCING LOW SPEED PRE-IGNITION EVENTS CHEVRON ORONITE COMPANY LLC (US) 2020-04-09 WO disclosed
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
US-20080227806-A1 Novel Drugs for Dementia AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2008-09-18 US disclosed
WO-2007038772-A1 NOVEL DRUGS FOR DEMENTIA AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227806-A1 Novel Drugs for Dementia CTSS, PRSS1, CBS NOTUM 372/4885MEN1 2586/4885KMT2A 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.